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OBJECTIVE—To identify distinct developmental patterns of diabetic retinopathy (DR) and
assess the risk factor levels of patients in these clusters.
RESEARCHDESIGNANDMETHODS—Acohortof3,343patientswithtype2diabetes
mellitus(T2DM)monitoredandtreatedintheDiabetesCareSystemWest-Friesland,theNether-
lands, was followed from 2 to 6 years. Risk factors were measured, and two-ﬁeld fundus photo-
graphs were taken annually and graded according to the EURODIAB study group. Latent class
growth modeling was used to identify distinct developmental patterns of DR over time.
RESULTS—Five clusters of patients with distinct developmental patterns of DR were identi-
ﬁed:A,patientswithoutanysignsofDR(88.9%);B,patientswithaslowregressionfromminimal
background to no DR (4.9%); C, patients with a slow progression from minimal background to
moderate nonproliferative DR (4.0%); D, patients with a fast progression from minimal or
moderate nonproliferative to (pre)proliferative or treated DR (1.4%); and E, patients with per-
sistentproliferativeDR(0.8%).PatientsinclustersAandBwerecharacterizedbylowerriskfactor
levels, such as diabetes duration, HbA1c, and systolic blood pressure compared with patients in
progressive clusters (C–E).
CONCLUSIONS—Clusters of patients with T2DM with markedly different patterns of DR
development were identiﬁed, including a cluster with regression of DR. These clusters enable a
more detailed examination of the inﬂuence of various risk factors on DR.
Diabetes Care 34:867–872, 2011
D
iabetic retinopathy (DR) isa serious
complication of type 2 diabetes
mellitus (T2DM) and one of the
main causes of blindness in the Western
working population (1). Treatment of DR
with photocoagulation and prevention
of onset of DR through treatment of
hyperglycemia and other risk factors are
effective (2,3). Therefore, international
guidelines recommend regular screening
for DR in patients with diabetes (4). Sev-
eral studies have shown that the preva-
lence of retinopathy as a complication of
diabetesdecreasedinrecentyearscompared
with the 1980s. It is hypothesized that
early detection of DR and adequate treat-
ment of both DR and diabetes might
have caused this decline in prevalence
(5,6). Nonetheless, because the preva-
lence of T2DM is still increasing (7), a
heavy burden on health care will be im-
posed because of increasing costs for di-
abetic treatment and prevention of
complications (8,9). Previous longitudi-
nal cohort studies, such as the Wisconsin
Epidemiological Study of Diabetic Reti-
nopathy, the UK Prospective Diabetes
Study, and the Hoorn Study, have identi-
ﬁed important associations between risk
factors for and onset of DR or progression
of DR (10–12). These studies considered
DR as an end point with varying deﬁni-
tions, but none of the previous studies
distinguished groups of patients with a
different course of development of DR in
time. To acknowledge these differential
courses during the development of DR,
time-dependent descriptions of the grad-
ing of DR in different groups of patients
areneededtohelpguidedeterminationof
screening intervals. The aims of the cur-
rent study were to identify and quantify
distinct time-dependent developmental
patternsofDRand toexaminerisk factors
associated with these patterns.
RESEARCH DESIGN AND
METHODS
Study population
Data were derived from a cohort (n =
4,933) of diabetic patients participating in
the Diabetes Care System West-Friesland
(DCS), the Netherlands, in the period
from 1998 to 2005. The DCS coordinates
regional diabetic care and provides ad-
ditional care to diabetic care given by
general practitioners. Details on this
care system have been published (13).
In brief, this system provides for annual
physical examinations, with assessment
of glucose control, cardiovascular risk
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ORIGINAL ARTICLEproﬁle, and complications of diabetes, in-
cludingfundusphotography,andsupports
self-management. Patient data of this an-
nual visit and therapeutic advice are pro-
vided to the general practitioner of the
patient to implement. In the study period
between 1998 and 2005, patients entered
the DCS in different years and with dif-
ferentdiabeticduration.Foreachpatient,
the year of entry was considered baseline
measurement (T0). Thus, patients who
entered in the year 1998 could provide
for up to eight visits. However, because
only 349 of the 3,343 included patients
had data at T7, we excluded the T7 visit
and used data from T0 to T6 in the anal-
ysis. For the present analysis of the de-
velopmental patterns of DR, we excluded
patients with type 1 diabetes (n =49 )a n d
patients with only one or no visit with
graded fundus photographs (n = 1,541).
Although statistically signiﬁcant, small
differences were seen between included
(n = 3,343) and excluded (n = 1,590) pa-
tients at T0; the excluded patients were
5.6 years older, included 6.2% more
women, had a 1.8-year longer duration
of diabetes, entered the DCS 1.7 years
later, had a 2 mmHg lower diastolic blood
pressure, had a 4 mmHg higher systolic
blood pressure, had a 0.6 lower BMI,
had a slightly more favorable lipid proﬁle,
andhad10%moreinsulinusethanpatients
who were included in the study. No signif-
icant differences were observed in fasting
plasma glucose (FPG), HbA1c, retinopathy
prevalence, and smoking behavior.
Measurements
Height and weight were measured in
barefoot patients wearing only light
clothes. Systolic and diastolic blood pres-
sures were measured on the right arm
after 5 min of rest in a seated position
using a random-zero sphygmomanome-
ter (Hawksley-Gelman, Lancing, Sussex,
UK); from 2003 on, an oscillometric de-
vicewasused(ColinPress-MateBP-8800,
Komaki City, Japan). HbA1c was mea-
suredwithhigh-performanceliquidchro-
matography. FPG was measured by
means of a hexokinase method (Roche
DiagnosticsGmbH,Mannheim,Germany).
Levels of total cholesterol, HDL choles-
terol, and triglycerides were measured
using enzymatic techniques (Boehringer-
Mannheim,Mannheim,Germany).Urinary
albumin-creatinine ratio in milligrams
per millimole was determined in an over-
night ﬁrst-voided urine sample. Urinary
albumin was measured by rate nephe-
lometry (Array Protein System; Beckman
Coulter, Fullerton,C A ) ,w i t ha na s s a y
threshold of 2 mg/L. Urinary and serum
creatinine were measured by a modiﬁed
Jaffé test. Information on current medi-
cation use, smoking (yes/no), and year
ofonsetofdiabeteswasobtainedbyself-
report.
Retinopathy
Until 2000, fundus photography of both
eyes was performed with a Kowa Pro
Fundus camera with green ﬁlter (Kowa
Optical Industry, Torrance, CA). Black
and white 35-mm photographs were
taken 30 min after mydriasis with 0.5%
tropicamide and 2.5% phenylephrine eye
drops. From the beginning of 2000 to
2004, fundus photography of both eyes
was performed with a nonmydriatic
Canon CR5 camera (Canon Inc., Tokyo,
Japan). In 2004, fundus photography of
both eyes was performed with a non-
mydriatic Topcon TRC NW 100 camera
(Topcon, Tokyo, Japan). All fundus pho-
tographs were 45 degrees of two ﬁelds:
one ﬁe l dc e n t e r e do nt h em a c u l aa n do n e
nasal ﬁeld with the optic disc positioned
on a disc-diameter from the temporal edge
of the ﬁeld, according to the EURODIAB
protocol (14). If fundus photography at
the DCS had failed or was missing, data
on DR were retrieved from the patient’s
medical ﬁle at the local hospital. All pho-
tographs were graded by an ophthalmol-
ogist according to the EURODIAB Study
grading system, in which grade 0 is “no
retinopathy,” grade 1 is “minimal non-
proliferative retinopathy,” grade 2 is
“moderate nonproliferative retinopathy,”
grade 3 is “severe nonproliferative or
preproliferative retinopathy,” grade 4
is “photocoagulated retinopathy,” and
grade 5 is “proliferative retinopathy.”
The EURODIAB grading does not pro-
vide for more detailed distinctions of
speciﬁc diabetic changes in the retina,
such as macular edema. In the DCS, the
EURODIAB grades 4 and 5 have been
combined in one grade, grade 4. In case
of photocoagulation at the local hospital,
a n ye x i s t i n gg r a d ei nt h ed a t ao ft h eD C S
was changed to EURODIAB grade 4 at all
time points after this therapy. If results of
the grading of both eyes were available,
the grading of the worst eye was used.
Statistical analysis
The year of entry in the DCS of each
individual was considered as the baseline
measurement (T0). The prevalence of DR
per grade was calculated at baseline, as
well as the prevalence of any DR (grades
1–4) at T0 to T6. Further analyses were
conducted in two parts.
In part one, latent class growth mod-
eling (LCGM) was used to identify dis-
tinct developmental patterns of DR (15).
LCGM is a relatively new statistical tech-
niqueusedtoanalyzeheterogeneityinthe
time course of, for example, DR. The un-
derlying aim of the technique is to model
this heterogeneity by identifying k num-
ber of distinct developmental patterns of
DR called “clusters.” Individuals are allo-
cated to one cluster on the basis of a sim-
ilarpatternofdevelopmentofretinopathy
at all measurements. The allocation is
done only once for each individual. To
determine the optimal number of
clusters, a “forward” approach was taken
starting with a model with one develop-
mental pattern, implying that all individ-
uals in the study had the same course of
DR. Subsequently, one cluster at a time
was added, and the model ﬁtw a sa s -
sessed by the Bayesian Information Cri-
terion (BIC), which is often used when
conducting such analyses (16). After
each step of adding a new cluster, the
model ﬁt was considered better if the
BIC decreased.Theﬁnalnumberofclus-
ters was derived on the basis of the for-
ward approach assessed by a low BIC
score and clinically relevant differences
between clusters. If addition of a new
cluster led to a model with two clinically
indistinguishable developmental clus-
ters, the model was not considered to
be improved.
Individualswithineachoftheclusters
have a probability of having each of the
ﬁve EURODIAB grades of retinopathy.
This probability varies over time and
reﬂects the prevalence of DR. Identiﬁca-
tion of the retinopathy grade with the
highestprobability at each timepointwas
used to derive a descriptive name of each
cluster. The LCGM analyses were con-
ducted with Mplus 5.21.
In part two of our analyses, differ-
ences between clusters in baseline char-
acteristics (mean [SD] or proportion)
were tested with an ANOVA with post
hocBonferroniorx
2tests.Baselinechar-
acteristics with a skewed distribution
were calculated as median (interquartile
range) within each cluster, and differen-
ces between clusters were analyzed by
Kruskal–Wallistest.Trendsinmeanlev-
els of HbA1c, systolic blood pressure,
and total cholesterol were graphically
compared between the clusters dur-
ing follow-up (SPSS 15.0.2, SPSS Inc.,
Chicago, IL).
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Patterns of diabetic retinopathyRESULTS
Prevalence of retinopathy stages
At baseline, our population with a mean
age of 61.0 years (SD 11.3), 52.7% of
whom were male, and a mean age at
diagnosis of diabetes of 56.9 years (SD
11.5 years) (Table 1) had a prevalence of
the separate EURODIAB grades of 87.4%
for grade 0, 9.1% for grade 1, 2.0% for
grade 2, 1.2% for grade 3, and 0.4% for
grade4.TheprevalenceofanyDR(grades
1–4) was 12.7% at baseline, 14.3% at T1,
15.1% at T2, 14.6% at T3, 18.7% at T4,
14.6%atT5,and16.9%atT6(Pvaluefor
trend = 0.001).
Course of retinopathy
On the basis of the lower Bayes’ Informa-
tionCriterionofamodelwithﬁveclusters
compared with a model with six clusters,
the optimal number of clusters with dis-
tinct developmental patterns of DR was
ﬁve (clusters A–E). This optimal number
was also conﬁrmed by clinical interpreta-
tionofthepatternsofdevelopmentofDR,
which were distinct in the ﬁve cluster
model. A model with six clusters did not
provide a further clinically distinguish-
able developmental pattern.
These patterns of DR are depicted as
mean EURODIAB grades per cluster in
Fig. 1. The largest cluster A (n=2,971,
88.9%) was characterized by “persistent
no retinopathy.” Within cluster A, the
probability for patients having no reti-
nopathy (grade 0) was 0.92 or more at
each of the 7 time points. The probabili-
ties are shown in Supplementary Fig. 1.
Cluster B (n=165, 4.9%) was character-
ized as “slow regression.” Within cluster
B, the highest probability for these pa-
tients was 0.81 of having either grade
0 or grade 1 retinopathy at T0, with a
higher probability of having grade 1
(0.56) than grade 0 (0.25). Not only did
the probability of having either grade 0 or
1 gradually increase over time to 0.99 at
T6, but after T2, the probability of having
grade 0 started being higher than the
probability of having grade 1. Cluster C
(n=135, 4.0%) was characterized as
“slow progression from minimal to mod-
erate retinopathy,” including patients
with a slow and gradual progression.
Within cluster C, patients had a probabil-
ity of 0.92 of having grade 0 or 1 at T0.
This probability decreased gradually over
time, and after T4 the probability of
having a higher grade (grade 2 or 3) had
increasedto0.22,whichfurtherincreased
to 0.35 at T6. Another cluster of pro-
gression was cluster D (n=47, 1.4%),
characterized as “fast progression from
minimal or moderate to (pre)prolifera-
tive or treated retinopathy.” After 1 year
theprobability ofhaving retinopathygrade
0, 1, or 2 already decreased for these pa-
tients from 0.81 to 0.62, with a further de-
crease through T2 and T3. After T4, the
probability of having retinopathy grade 3
or4was0.91ormoreinclusterD.Theﬁnal
Table 1—Differences in baseline characteristics between clusters of distinct developmental patterns of DR in the DCS population,
the Netherlands
Total
DCS
population
Cluster A:
“persistent
no DR”
Cluster B:
“slow
regression”
Cluster C:
“slow progression
from minimal
to moderate DR”
Cluster D:
“fast progression
NPDR to PDR
or treated DR”
Cluster E:
“persistent PDR
or treated DR”
P , 0.05
between
clusters
n (%) 3,343 (100) 2,971 (88.9) 165 (4.9) 135 (4.0) 47 (1.4) 25 (0.8)
Age, years 61.0 6 11.3 60.7 6 11.3 63.6 6 10.6 62.7 6 12.4 62.2 6 10.1 63.3 6 13.7 A , B
Male, % 52.7 52.9 60.6 47.4 40.4 36.0 P =0 . 0 2 3
Diabetes duration, years 2 (1–5) 2 (1–5) 4 (1–8.3) 5 (3–10) 9 (3.5–13) 12.5 (7.75–19) P , 0.001
HbA1c,% 7 . 76 1.8 7.6 6 1.8 7.8 6 1.7 8.4 6 1.8 9.1 6 1.9 9.0 6 1.8 A , C/D/E,
B , D/E
FPG, mmol/L 8.9 6 2.5 8.7 6 2.5 9.1 6 2.6 10.2 6 2.8 10.5 6 3.3 11.3 6 4.2 A , C/D/E,
B , C/D/E
Systolic blood pressure,
mmHg 142 6 21 142 6 21 145 6 22 150 6 23 143 6 23 153 6 25 A , C
Diastolic blood pressure,
mmHg 84 6 11 84 6 11 84 6 10 86 6 11 83 6 11 83 6 15 NS
BMI, kg/m
2 30.0 6 5.3 30.1 6 5.3 28.7 6 4.9 29.5 6 4.6 29.8 6 5.4 32.6 6 5.5 B , A/E
Creatinine 93.0 6 16.4 93.0 6 16.2 94.7 6 17.3 92.3 6 16.7 91.5 6 20.1 97.8 6 21.6 NS
Albumin–creatinine ratio 3.7 6 14.9 3.2 6 14.0 5.9 6 19.9 7.0 6 19.8 9.5 6 24.2 12.6 6 23.3 A , C/D/E
Total cholesterol, mmol/L 5.5 6 1.1 5.5 6 1.1 5.4 6 0.9 5.8 6 1.1 5.8 6 1.2 5.9 6 1.0 B , C
HDL cholesterol, mmol/L 1.20 6 0.34 1.19 6 0.32 1.23 6 0.33 1.25 6 0.62 1.17 6 0.32 1.24 6 0.37 NS
LDL cholesterol, mmol/L 3.4 6 1.0 3.4 6 1.0 3.4 6 0.8 3.7 6 1.0 3.7 6 1.0 3.6 6 0.9 NS
Triglycerides, mmol/L 2.0 6 1.4 2.1 6 1.4 1.8 6 0.9 2.1 6 1.5 2.2 6 1.6 2.3 6 1.2 NS
Smoking, % 21.2 21.6 23.6 14.1 14.9 12.6 NS
OAD use, % 67.8 67.0 73.4 82.0 59.1 70.8 P =0 . 0 0 2
Insulin use, % 7.7 6.0 13.9 20.3 36.4 41.7 P , 0.001
Both OAD medication
and insulin, % 3.9 3.3 7.0 11.7 6.8 12.5 P , 0.001
Antihypertensive use, % 47.7 47.7 56.3 45.3 27.3 41.7 P =0 . 1 3
Antilipid use, % 22.4 23.3 17.1 13.3 15.9 16.7 P =0 . 2 2
Data represent mean 6 SD, proportions, or median (interquartile range). Between-cluster differences were tested with ANOVA and post hoc Bonferroni for mean
values, with x
2 tests for proportions and Kruskal–Wallis test for median values. NPDR, nonproliferative DR; PDR, proliferative DR; NS, nonsigniﬁcant; OAD, oral
antidiabetic.
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Zavrelova and Associatescluster E (n=25, 0.8%) was characterized
as “persistent proliferative or treated reti-
nopathy.” The probability of having reti-
nopathy grade 3 or 4 for these patients
was 0.78 at T0, which even increased after
1y e a rt o$0.95.
Characteristics
Between cluster differences of baseline
characteristics can be seen in Table 1. At
T0, patients in cluster A with “persistent
no retinopathy” had a statistically signiﬁ-
cantly lower diabetes duration than pa-
tients in the other clusters. Mean HbA1c
levels were lower in cluster A patients
withatleast0.8%comparedwithpatients
in other clusters except for patients in
cluster B “slow regression.” HbA1c in pa-
tients of cluster B “slow regression” was
not statistically different from the HbA1c
of patients in cluster C “slow progression
from minimal to moderate retinopathy,”
but the HbA1c in patients of cluster B was
1.3% lower than in patients of clusters D
and E. Mean FPG was lower in patients of
both clusters A and B compared with pa-
tients in clusters C, D, and E. In cluster A,
67% of the patients used oral antidiabetic
medication, which was higher than in the
“fast progressing” cluster D but lower
than in all other clusters. Insulin use
was highest in the progressive clusters
C,D,andE,andlowestinclusterA.Com-
bination therapy of insulin and oral anti-
diabetic medication was also signiﬁcantly
lower in cluster A compared with all
other clusters. An 8 mmHg lower systolic
blood pressure was seen in patients in
clusterA“persistentnoretinopathy”com-
pared with patients in cluster C “slow
progression from minimal to moderate
retinopathy” at baseline. In both clusters
A and C, a similar proportion of patients
used antihypertensive medication (47.7
vs. 45.3%) at baseline. HbA1c,s y s t o l i c
blood pressure, and total cholesterol are
shown per cluster as means at each time
p o i n ti nF i g .2 .F o rH b A 1c and total
cholesterol, a decrease was seen in all
clusters over time. Patients in clusters A
and B, the nonprogressive clusters, had
lower mean values of HbA1c and total
cholesterol than patients in the progres-
sive clusters C, D, and E over time. An
increase over time for all clusters was
seen in systolic blood pressure. For pa-
tients in cluster C, who started to show
an increase in retinopathy severity after
T4, an increase of systolic blood pressure
with 615 mmHg was seen between T3
and T5. Patients in cluster D, with an in-
crease in retinopathy severity after T1,
showed an increase in systolic blood pres-
sureof;10mmHgafterT1.Systolicblood
pressure also increased in clusters A and B,
but this increase never exceeded 5 mmHg
in 1 year.
CONCLUSIONS—In this study on
t h ec o u r s eo fD R ,w ei d e n t i ﬁed ﬁve
clusters of developmental patterns of DR
in patients with T2DM and assessed the
risk factor levels of these clusters. The
largest cluster (A) represents diabetic
patients who did not develop any DR
over a time period of 6 years. One cluster
showing regression (B) represented pa-
tientswhohadahighprobabilityofhaving
minimal DR, which disappeared over
time.Twoprogressiveclusters(CandD)
were identiﬁed that differed from each
other in severity and in speed of devel-
oping DR. The smallest cluster (E) con-
sisted of patients who had persistently
(pre)proliferative DR or photocoagulation
scars. Thus, in a large cohort of patients
with T2DM, the majority of patients did
not develop DR. Of the 372 patients in
clusters B, C, D, and E who did develop
DR, more than 44% (n=165) showed re-
gression in cluster B. The two progressive
clusters C and D had persistently higher
levels of risk factors than clusters A and B,
withnoorlittleretinopathy.Steepincreases
in systolic blood pressure in these progres-
sive clusters were observed, which seemed
to coincide with the point in time at which
progression of DR occurred.
To our knowledge, LCGM has never
been applied to longitudinal data on DR.
LCGM is applicable because of the het-
erogeneous nature of DR. These analyses
were performed in a large population of
patients with T2DM, representative of
85% of the diabetic patients in the region
withamaximumfollow-upof6years.We
accurately measured important risk fac-
tors within a standardized care system
and at yearly time intervals. We used the
EURODIAB grading system to assess
DR, a grading system recommended for
large epidemiologic studies (14). How-
ever, a limitation of our study is the use
of one combined grade for EURODIAB
grades 4 and 5; thus, no distinction can
be made between progression to prolifer-
ative DR (PDR) or treatment of DR with
photocoagulation. Furthermore, because
the EURODIAB was not designed to as-
sess maculopathy, this study does not
provide details on different causes of pro-
gression.Nonetheless,toobtainanimpres-
sion of clinically relevant progression of
DR, the use of the EURODIAB grading
with 4/5 combined without more detailed
grading seems to be sufﬁcient.
The current study was performed in a
diabetic population of mainly Caucasian
origin, with a mean age of 61.0 years.
Therefore, these results may not be rep-
resentative of a younger or non-Caucasian
population. Furthermore, the study pop-
ulation consisted of patients with T2DM
with a variety of diabetic duration and
relativelywelltreatedhyperglycemia.How-
ever,the prevalence of an HbA1c.8.0% at
some point between T0 and T6 was 47%,
and the prevalence of an HbA1c .10.0%
was 17%. Nonetheless, less heterogeneous
clusters or different clusters of develop-
mental patterns might be found if analyses
would berepeatedindifferentpopulations,
Figure 1—Course of DR over 6 years in type 2 diabetic patients in the DCS, the Netherlands,
1998–2005. The year of entry in the DCS was considered baseline (T0). ●,c l u s t e rA“persistent
noDR.”○,clusterB“slowregression.”▲,clusterC“slowprogressionfromminimaltomoderate
nonproliferative DR.” △,clusterD“fast progressionnonproliferative DR to PDRortreated DR.”
■,c l u s t e rE“persistent PDR or treated DR.” PDR, proliferative DR.
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Patterns of diabetic retinopathye.g., with type 1 diabetes or new-onset
T2DM, with a longer follow-up than the
time frame of 6 years in our study or with
higher levels of blood glucose.
Severalimportantlongitudinalstudies,
whichhavestudied risk factorsinﬂuencing
the onset or the progression of DR, differ
from the current study. First, the aim of
these studies was to describe the associ-
ations of onset or progression of DR with
risk factors, but none of these studies
were designed to study the developmental
pattern of DR based on yearly measure-
ments. Second, some of these studies used
morethantwofollow-upmeasures(10,17),
b u tm o s th a do n l yr e t i n o p a t h yd a t ao n
baseline and one follow-up measurement
(11,18), and thus the outcome was inci-
dence of new-onset DR or incidence of a
certain degree of progression of DR. This
hampers a sound analysis of progression
and regression, because the possibility
of regression of DR was not taken in ac-
count. We show that regression does oc-
cur in a small subgroup of patients,
cluster B. Although small, this cluster is
the second largest cluster after cluster A
with “persistent no retinopathy.” Previ-
ous cross-sectional studies on DR preva-
lence have also shown that most diabetic
patients have no DR or mild background
DR. We also found that the majority of
diabetic patients (88.9%) do not develop
DR in a 6-year period. This might have
consequences for advice on differential
possible screening intervals in selected
patients.
In the current study, clusters with
progressive or stable high levels of DR
have high levels of some risk factors
compared with nonprogressive clusters.
These results are in line with the afore-
mentionedcohortstudies, such as theUK
Prospective Diabetes Study, EURODIAB,
and Wisconsin Epidemiological Study of
Diabetic Retinopathy, which showed as-
sociationsofincidenceandprogressionof
DR among others with HbA1c,b l o o d
pressure,anddiabeticduration.Thesteep
increases of systolic blood pressure in the
progressive clusters, coinciding with the
time at which retinopathy progressed,
suggest that progression of DR is inﬂu-
enced to a large extent by blood pressure
anddiabetesduration.Nonetheless,these
clustersalsohavehighlevelsofbloodglu-
cose and other risk factors. Thus, future
research should focus on the inﬂuence of
risk factors on both progression and re-
gression of DR.
In summary, we have described ﬁve
clusters of distinct developmental pat-
terns of DR that enable a more detailed
examination of the inﬂuence of various
risk factors on the course of retinopathy.
The majority of patients with T2DM in
thispopulationdidnotoronly minimally
developed retinopathy over a period of
6 years. These patients showed lower risk
factor levels of diabetic duration, HbA1c,
FPG, and systolic blood pressure com-
pared with patients in the two other small
clusters of diabetic patients who showed
progression of DR. Patients in these two
Figure 2—Course of risk factors of DR over time. Mean HbA1c (A), systolic blood pressure (B),
andtotalcholesterol(C)byclustersofthedevelopmentofDR.●,clusterA“persistentnoDR.”○,
cluster B “slow regression.” ▲,c l u s t e rC“slow progression from minimal to moderate non-
proliferative DR.” △,c lu s t e rD“fast progression nonproliferative DR to PDR or treated DR.” ■,
cluster E “persistent PDR or treated DR.” PDR, proliferative DR.
care.diabetesjournals.org DIABETES CARE, VOLUME 34, APRIL 2011 871
Zavrelova and Associatesprogressive clusters are at high risk of
persistent PDR and are therefore in
need of strict and regular screening. Fur-
ther research is needed to investigate how
to distinguish patients in progressive de-
velopmental clusters from patients with
no or minimal background DR.
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